Lanean...

Secukinumab in the treatment of psoriasis: patient selection and perspectives

Secukinumab is a human monoclonal antibody targeting IL-17A that has been approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab has proven to be both highly e...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Psoriasis (Auckl)
Egile Nagusiak: Yang, Eric J, Beck, Kristen M, Liao, Wilson
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2018
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6202001/
https://ncbi.nlm.nih.gov/pubmed/30425963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/PTT.S146004
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!